Pathways' Pick of the Week: A Record Year for Novel Devices

article image
ARTICLE SUMMARY:

CDRH approved a record number of novel devices in 2023. Excerpted from Pathways' Picks January 17: “China on Real-World Studies, IMDRF Heads to DC, Medicare Picks, and EU News.

FDA’s device center authorized 124 devices that it categorizes as “novel” in 2023, “the highest number of novel medical devices on record,” CDRH announced in the January 17 release of its 2023 annual report. The novel device count, which excludes emergency use authorizations, totals original and panel-track PMAs, De Novos, original Humanitarian Device Exemptions, and Breakthrough Device 510(k) clearances. A few other factoids from the annual report:

  • CDRH authorized (PMA, De Novo, and 510(k) 29 Breakthrough Devices in 2023, the most since the program was launched;  
  • 21 device have transitioned from EUAs to traditional marketing authorizations; and
  • All 141 positions funded by MDUFA V for FY 2023 were filed.
Continue reading Pathways’ Picks here.
×



Articles from David Filmore:

Regulatory & Reimbursement

Medicare Cuts, FDA Panels, China GMP Update, and Global Picks

In this week’s Pathways Picks: CMS trims procedure payments in the name of efficiency, reimburses ADHD digital therapeutics, and approves real-world renal denervation study; FDA looks to cardio and AI advisory panels; China revamps and harmonizes GMP standards; India finalizes Class A device exemptions; South Korea invests in device innovation; EU forms new combo product group; and more.

Read Article